I don't have the greatest knowledge in this area, but my understanding is a small sample size (even though more difficult) would be to show proof of concept - or efficacy - which in my opion is already done in part, but a large ph2 or ph3 trial will still be needed before potentially becoming commercialised. Which is the outcome I would expect to see with Xanamen in 4-5 yrs.
So if I were on the board and putting a strategic plan together I would be pushing for a large trial straight away. Even if that means a CR is required.
Happy to be corrected on what the path to commercialisation is (excluding fast track, etc).
Cheers
IMO, etc
I don't have the greatest knowledge in this area, but my...
Add ACW (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
2.7¢ |
Change
-0.002(6.90%) |
Mkt cap ! $68.22M | |||
| Open | High | Low | Value | Volume |
| 2.9¢ | 2.9¢ | 2.7¢ | $23.80K | 831.8K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 237694 | 2.6¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 3.0¢ | 1017300 | 2 |
View Market Depth
| Last trade - 14.52pm 04/06/2024 (20 minute delay) ? |
|
|||||
|
Last
2.7¢ |
Change
-0.002 ( 6.90 %) |
||||
| Open | High | Low | Volume | ||
| 2.9¢ | 2.9¢ | 2.7¢ | 677943 | ||
| Last updated 15.51pm 04/06/2024 ? | |||||
| ACW (ASX) Chart |